|
1
|
Balkwill F and Mantovani A: Inflammation
and cancer: back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kuper H, Adami HO and Trichopoulos D:
Infections as a major preventable cause of human cancer. J Intern
Med. 248:171–183. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shacter E and Weitzman SA: Chronic
inflammation and cancer. Oncology (Williston Park). 16:217–232.
2002.PubMed/NCBI
|
|
4
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kusmartsev S and Gabrilovich DI: Immature
myeloid cells and cancer-associated immune suppression. Cancer
Immunol Immunother. 51:293–298. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Serafini P, De Santo C, Marigo I,
Cingarlini S, Dolcetti L, Gallina G, Zanovello P and Bronte V:
Derangement of immune responses by myeloid suppressor cells. Cancer
Immunol Immunother. 53:64–72. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vakkila J and Lotze MT: Inflammation and
necrosis promote tumour growth. Nat Rev Immunol. 4:641–648. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aller MA, Arias JL, Nava MP and Arias J:
Posttraumatic inflammation is a complex response based on the
pathological expression of the nervous, immune, and endocrine
functional systems. Exp Biol Med. 229:170–181. 2004. View Article : Google Scholar
|
|
9
|
Denko NC, Fontana LA, Hudson KM, Sutphin
PD, Raychaudhuri S, Altman R and Giaccia AJ: Investigating hypoxic
tumor physiology through gene expression patterns. Oncogene.
22:5907–5914. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Whiteside TL: The tumor microenvironment
and its role in promoting tumor growth. Oncogene. 27:5904–5912.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Srivastava MK, Andersson Å, Zhu L,
Harris-White M, Lee JM, Dubinett S and Sharma S: Myeloid suppressor
cells and immune modulation in lung cancer. Immunotherapy.
4:291–304. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gallucci S and Matzinger P: Danger
signals: SOS to the immune system. Curr Opin Immunol. 13:114–119.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Whiteside TL: Immune suppression in
cancer: effects on immune cells, mechanisms and future therapeutic
intervention. Semin Cancer Biol. 16:3–15. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smyth MJ, Dunn GP and Schreiber RD: Cancer
immunosurveillance and immunoediting: The roles of immunity in
suppressing tumor development and shaping tumor immunogenicity. Adv
Immunol. 90:1–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Poggi A and Zocchi MR: Mechanisms of tumor
escape: role of tumor microenvironment in inducing apoptosis of
cytolytic effector cells. Arch Immunol Ther Exp. 54:323–333. 2006.
View Article : Google Scholar
|
|
16
|
Strober S: Natural suppressor (NS) cells,
neonatal tolerance, and total lymphoid irradiation: exploring
obscure relationships. Annu Rev Immunol. 2:219–237. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gabrilovich DI, Velders MP, Sotomayor EM
and Kast WM: Mechanism of immune dysfunction in cancer mediated by
immature Gr-1+ myeloid cells. J Immunol. 166:5398–5406. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bronte V, Serafini P, De Santo C, Marigo
I, Tosello V, Mazzoni A, Segal DM, Staib C, Lowel M, Sutter G, et
al: IL-4-induced arginase 1 suppresses alloreactive T cells in
tumor-bearing mice. J Immunol. 170:270–278. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Van Ginderachter JA, Brys L, De
Baetselier P, Raes G and Geldhof AB: Nitric oxide-independent CTL
suppression during tumor progression: association with
arginase-producing (M2) myeloid cells. J Immunol. 170:5064–5074.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mazzoni A, Bronte V, Visintin A, Spitzer
JH, Apolloni E, Serafini P, Zanovello P and Segal DM: Myeloid
suppressor lines inhibit T cell responses by an NO-dependent
mechanism. J Immunol. 168:689–695. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Rodriguez PC, Quiceno DG, Zabaleta J,
Ortiz B, Zea AH, Piazuelo MB, Delgado A, Correa P, Brayer J,
Sotomayor EM, et al: Arginase I production in the tumor
microenvironment by mature myeloid cells inhibits T-cell receptor
expression and antigen-specific T-cell responses. Cancer Res.
64:5839–5849. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bronte V, Apolloni E, Cabrelle A, Ronca R,
Serafini P, Zamboni P, Restifo NP and Zanovello P: Identification
of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of
activating or suppressing CD8(+) T cells. Blood. 96:3838–3846.
2000.PubMed/NCBI
|
|
23
|
Kusmartsev S and Gabrilovich DI:
Inhibition of myeloid cell differentiation in cancer: the role of
reactive oxygen species. J Leukoc Biol. 74:186–196. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Q, Pan PY, Gu P, Xu D and Chen SH: Role
of immature myeloid Gr-1+ cells in the development of antitumor
immunity. Cancer Res. 64:1130–1139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gabrilovich DI: Molecular mechanisms and
therapeutic reversal of immune suppression in cancer. Curr Cancer
Drug Targets. 7:12007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Youn JI, Nagaraj S, Collazo M and
Gabrilovich DI: Subsets of myeloid-derived suppressor cells in
tumor-bearing mice. J Immunol. 181:5791–5802. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Youn JI and Gabrilovich DI: The biology of
myeloid-derived suppressor cells: the blessing and the curse of
morphological and functional heterogeneity. Eur J Immunol.
40:2969–2975. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Condamine T and Gabrilovich DI: Molecular
mechanisms regulating myeloid-derived suppressor cell
differentiation and function. Trends Immunol. 32:19–25. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zea AH, Rodriguez PC, Atkins MB, Hernandez
C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A,
O'Neill A, et al: Arginase-producing myeloid suppressor cells in
renal cell carcinoma patients: a mechanism of tumor evasion. Cancer
Res. 65:3044–3048. 2005.PubMed/NCBI
|
|
30
|
Poschke I, Mougiakakos D, Hansson J,
Masucci GV and Kiessling R: Immature immunosuppressive
CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and
overexpress CD80, CD83, and DC-Sign. Cancer Res. 70:4335–4345.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Srivastava MK, Bosch JJ, Thompson JA,
Ksander BR, Edelman MJ and Ostrand-Rosenberg S: Lung cancer
patients' CD4(+) T cells are activated in vitro by MHC II
cell-based vaccines despite the presence of myeloid-derived
suppressor cells. Cancer Immunol Immunother. 57:1493–1504. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Almand B, Clark JI, Nikitina E, van Beynen
J, English NR, Knight SC, Carbone DP and Gabrilovich DI: Increased
production of immature myeloid cells in cancer patients: a
mechanism of immunosuppression in cancer. J Immunol. 166:678–689.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Peláez B, Campillo JA, López-Asenjo JA and
Subiza JL: Cyclophosphamide induces the development of early
myeloid cells suppressing tumor cell growth by a nitric
oxide-dependent mechanism. J Immunol. 166:6608–6615. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Goddard S, Youster J, Morgan E and Adams
DH: Interleukin-10 secretion differentiates dendritic cells from
human liver and skin. Am J Pathol. 164:511–519. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Halliday GM and Le S: Transforming growth
factor-β produced by progressor tumors inhibits, while IL-10
produced by regressor tumors enhances, Langerhans cell migration
from skin. Int Immunol. 13:1147–1154. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chomarat P, Banchereau J, Davoust J and
Palucka AK: IL-6 switches the differentiation of monocytes from
dendritic cells to macrophages. Nat Immunol. 1:510–514. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Gabrilovich DI, Chen HL, Girgis KR,
Cunningham HT, Meny GM, Nadaf S, Kavanaugh D and Carbone DP:
Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dendritic cells. Nat Med.
2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hammad H, de Heer HJ, Soullie T,
Hoogsteden HC, Trottein F and Lambrecht BN: Prostaglandin D2
inhibits airway dendritic cell migration and function in steady
state conditions by selective activation of the D prostanoid
receptor 1. J Immunol. 171:3936–3940. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jing H, Vassiliou E and Ganea D:
Prostaglandin E2 inhibits production of the inflammatory chemokines
CCL3 and CCL4 in dendritic cells. J Leukoc Biol. 74:868–879. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Schnurr M, Toy T, Shin A, Hartmann G,
Rothenfusser S, Soellner J, Davis ID, Cebon J and Maraskovsky E:
Role of adenosine receptors in regulating chemotaxis and cytokine
production of plasmacytoid dendritic cells. Blood. 103:1391–1397.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Murdoch C, Muthana M, Coffelt SB and Lewis
CE: The role of myeloid cells in the promotion of tumour
angiogenesis. Nat Rev Cancer. 8:618–631. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sica A and Bronte V: Altered macrophage
differentiation and immune dysfunction in tumor development. J Clin
Invest. 117:1155–1166. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bunt SK, Yang L, Sinha P, Clements VK,
Leips J and Ostrand-Rosenberg S: Reduced inflammation in the tumor
microenvironment delays the accumulation of myeloid-derived
suppressor cells and limits tumor progression. Cancer Res.
67:10019–10026. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bunt SK, Sinha P, Clements VK, Leips J and
Ostrand-Rosenberg S: Inflammation induces myeloid-derived
suppressor cells that facilitate tumor progression. J Immunol.
176:284–290. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Jiang H, Gebhardt C, Umansky L, Beckhove
P, Schulze TJ, Utikal J and Umansky V: Elevated chronic
inflammatory factors and myeloid-derived suppressor cells indicate
poor prognosis in advanced melanoma patients. Int J Cancer.
136:2352–2360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Blaser MJ, Chyou PH and Nomura A: Age at
establishment of Helicobacter pylori infection and gastric
carcinoma, gastric ulcer, and duodenal ulcer risk. Cancer Res.
55:562–565. 1995.PubMed/NCBI
|
|
47
|
Ernst PB and Gold BD: The disease spectrum
of Helicobacter pylori: the immunopathogenesis of gastroduodenal
ulcer and gastric cancer. Annu Rev Microbiol. 54:615–640. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kohanbash G, McKaveney K, Sakaki M, Ueda
R, Mintz AH, Amankulor N, Fujita M, Ohlfest JR and Okada H: GM-CSF
promotes the immunosuppressive activity of glioma-infiltrating
myeloid cells through interleukin-4 receptor-α. Cancer Res.
73:6413–6423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Sade-Feldman M, Kanterman J, Ish-Shalom E,
Elnekave M, Horwitz E and Baniyash M: Tumor necrosis factor-α
blocks differentiation and enhances suppressive activity of
immature myeloid cells during chronic inflammation. Immunity.
38:541–554. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Polz J, Remke A, Weber S, Schmidt D,
Weber-Steffens D, Pietryga-Krieger A, Müller N, Ritter U, Mostböck
S and Männel DN: Myeloid suppressor cells require membrane TNFR2
expression for suppressive activity. Immun Inflamm Dis. 2:121–130.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Sinha P, Okoro C, Foell D, Freeze HH,
Ostrand-Rosenberg S and Srikrishna G: Proinflammatory S100 proteins
regulate the accumulation of myeloid-derived suppressor cells. J
Immunol. 181:4666–4675. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cheng P, Corzo CA, Luetteke N, Yu B,
Nagaraj S, Bui MM, Ortiz M, Nacken W, Sorg C, Vogl T, et al:
Inhibition of dendritic cell differentiation and accumulation of
myeloid-derived suppressor cells in cancer is regulated by S100A9
protein. J Exp Med. 205:2235–2249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tsan MF: Toll-like receptors, inflammation
and cancer. Semin Cancer Biol. 16:32–37. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Vaknin I, Blinder L, Wang L, Gazit R,
Shapira E, Genina O, Pines M, Pikarsky E and Baniyash M: A common
pathway mediated through Toll-like receptors leads to T- and
natural killer-cell immunosuppression. Blood. 111:1437–1447. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Nakagomi H, Petersson M, Magnusson I,
Juhlin C, Matsuda M, Mellstedt H, Taupin JL, Vivier E, Anderson P
and Kiessling R: Decreased expression of the signal-transducing ζ
chains in tumor-infiltrating T-cells and NK cells of patients with
colorectal carcinoma. Cancer Res. 53:5610–5612. 1993.PubMed/NCBI
|
|
56
|
Matsuda M, Petersson M, Lenkei R, Taupin
JL, Magnusson I, Mellstedt H, Anderson P and Kiessling R:
Alterations in the signal-transducing molecules of T cells and NK
cells in colorectal tumor-infiltrating, gut mucosal and peripheral
lymphocytes: correlation with the stage of the disease. Int J
Cancer. 61:765–772. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lai P, Rabinowich H, Crowley-Nowick PA,
Bell MC, Mantovani G and Whiteside TL: Alterations in expression
and function of signal-transducing proteins in tumor-associated T
and natural killer cells in patients with ovarian carcinoma. Clin
Cancer Res. 2:161–173. 1996.PubMed/NCBI
|
|
58
|
Kono K, Ressing ME, Brandt RM, Melief CJ,
Potkul RK, Andersson B, Petersson M, Kast WM and Kiessling R:
Decreased expression of signal-transducing ζ chain in peripheral T
cells and natural killer cells in patients with cervical cancer.
Clin Cancer Res. 2:1825–1828. 1996.PubMed/NCBI
|
|
59
|
Kurt RA, Urba WJ, Smith JW and Schoof DD:
Peripheral T lymphocytes from women with breast cancer exhibit
abnormal protein expression of several signaling molecules. Int J
Cancer. 78:16–20. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Kuss I, Saito T, Johnson JT and Whiteside
TL: Clinical significance of decreased ζ chain expression in
peripheral blood lymphocytes of patients with head and neck cancer.
Clin Cancer Res. 5:329–334. 1999.PubMed/NCBI
|
|
61
|
Healy CG, Simons JW, Carducci MA, DeWeese
TL, Bartkowski M, Tong KP and Bolton WE: Impaired expression and
function of signal-transducing ζ chains in peripheral T cells and
natural killer cells in patients with prostate cancer. Cytometry.
32:109–119. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Ezernitchi AV, Vaknin I, Cohen-Daniel L,
Levy O, Manaster E, Halabi A, Pikarsky E, Shapira L and Baniyash M:
TCR ζ downregulation under chronic inflammation is mediated by
myeloid suppressor cells differentially distributed between various
lymphatic organs. J Immunol. 177:4763–4772. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Baniyash M: TCR ζ-chain downregulation:
curtailing an excessive inflammatory immune response. Nat Rev
Immunol. 4:675–687. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Baniyash M: Chronic inflammation,
immunosuppression and cancer: new insights and outlook. Semin
Cancer Biol. 16:80–88. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Gabrilovich D, Ishida T, Oyama T, Ran S,
Kravtsov V, Nadaf S and Carbone DP: Vascular endothelial growth
factor inhibits the development of dendritic cells and dramatically
affects the differentiation of multiple hematopoietic lineages in
vivo. Blood. 92:4150–4166. 1998.PubMed/NCBI
|
|
66
|
Wang T, Niu G, Kortylewski M, Burdelya L,
Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola
D, et al: Regulation of the innate and adaptive immune responses by
Stat-3 signaling in tumor cells. Nat Med. 10:48–54. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Marigo I, Dolcetti L, Serafini P,
Zanovello P and Bronte V: Tumor-induced tolerance and immune
suppression by myeloid derived suppressor cells. Immunol Rev.
222:162–179. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Serafini P, Borrello I and Bronte V:
Myeloid suppressor cells in cancer: recruitment, phenotype,
properties, and mechanisms of immune suppression. Semin Cancer
Biol. 16:53–65. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Bronte V, Chappell DB, Apolloni E,
Cabrelle A, Wang M, Hwu P and Restifo NP: Unopposed production of
granulocyte-macrophage colony-stimulating factor by tumors inhibits
CD8+ T cell responses by dysregulating antigen-presenting cell
maturation. J Immunol. 162:5728–5737. 1999.PubMed/NCBI
|
|
70
|
Serafini P, Carbley R, Noonan KA, Tan G,
Bronte V and Borrello I: High-dose granulocyte-macrophage
colony-stimulating factor-producing vaccines impair the immune
response through the recruitment of myeloid suppressor cells.
Cancer Res. 64:6337–6343. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Fujita M, Kohanbash G, Fellows-Mayle W,
Hamilton RL, Komohara Y, Decker SA, Ohlfest JR and Okada H: COX-2
blockade suppresses gliomagenesis by inhibiting myeloid-derived
suppressor cells. Cancer Res. 71:2664–2674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Mundy-Bosse BL, Lesinski GB, Jaime-Ramirez
AC, Benninger K, Khan M, Kuppusamy P, Guenterberg K, Kondadasula
SV, Chaudhury AR, La Perle KM, et al: Myeloid-derived suppressor
cell inhibition of the IFN response in tumor-bearing mice. Cancer
Res. 71:5101–5110. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
McKenna KC, Beatty KM, Bilonick RA,
Schoenfield L, Lathrop KL and Singh AD: Activated CD11b+CD15+
granulocytes increase in the blood of patients with uveal melanoma.
Invest Ophthalmol Vis Sci. 50:4295–4303. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Young MR, Petruzzelli GJ, Kolesiak K,
Achille N, Lathers DM and Gabrilovich DI: Human squamous cell
carcinomas of the head and neck chemoattract immune suppressive
CD34(+) progenitor cells. Hum Immunol. 62:332–341. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Filipazzi P, Valenti R, Huber V, Pilla L,
Canese P, Iero M, Castelli C, Mariani L, Parmiani G and Rivoltini
L: Identification of a new subset of myeloid suppressor cells in
peripheral blood of melanoma patients with modulation by a
granulocyte-macrophage colony-stimulation factor-based antitumor
vaccine. J Clin Oncol. 25:2546–2553. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Achberger S, Aldrich W, Tubbs R, Crabb JW,
Singh AD and Triozzi PL: Circulating immune cell and microRNA in
patients with uveal melanoma developing metastatic disease. Mol
Immunol. 58:182–186. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Danna EA, Sinha P, Gilbert M, Clements VK,
Pulaski BA and Ostrand-Rosenberg S: Surgical removal of primary
tumor reverses tumor-induced immunosuppression despite the presence
of metastatic disease. Cancer Res. 64:2205–2211. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Sinha P, Clements VK and Ostrand-Rosenberg
S: Reduction of myeloid-derived suppressor cells and induction of
M1 macrophages facilitate the rejection of established metastatic
disease. J Immunol. 174:636–645. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Almand B, Resser JR, Lindman B, Nadaf S,
Clark JI, Kwon ED, Carbone DP and Gabrilovich DI: Clinical
significance of defective dendritic cell differentiation in cancer.
Clin Cancer Res. 6:1755–1766. 2000.PubMed/NCBI
|
|
80
|
Tinder TL, Subramani DB, Basu GD, Bradley
JM, Schettini J, Million A, Skaar T and Mukherjee P: MUC1 enhances
tumor progression and contributes toward immunosuppression in a
mouse model of spontaneous pancreatic adenocarcinoma. J Immunol.
181:3116–3125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wolf AM, Wolf D, Steurer M, Gastl G,
Gunsilius E and Grubeck-Loebenstein B: Increase of regulatory T
cells in the peripheral blood of cancer patients. Clin Cancer Res.
9:606–612. 2003.PubMed/NCBI
|
|
82
|
Terabe M and Berzofsky JA:
Immunoregulatory T cells in tumor immunity. Curr Opin Immunol.
16:157–162. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Cuenca A, Cheng F, Wang H, Brayer J, Horna
P, Gu L, Bien H, Borrello IM, Levitsky HI and Sotomayor EM:
Extra-lymphatic solid tumor growth is not immunologically ignored
and results in early induction of antigen-specific T-cell anergy:
dominant role of cross-tolerance to tumor antigens. Cancer Res.
63:9007–9015. 2003.PubMed/NCBI
|
|
84
|
Schmidt-Wolf IG, Dejbakhsh-Jones S,
Ginzton N, Greenberg P and Strober S: T-cell subsets and suppressor
cells in human bone marrow. Blood. 80:3242–3250. 1992.PubMed/NCBI
|
|
85
|
Young MR, Wright MA, Matthews JP, Malik I
and Prechel M: Suppression of T cell proliferation by tumor-induced
granulocyte-macrophage progenitor cells producing transforming
growth factor-β and nitric oxide. J Immunol. 156:1916–1922.
1996.PubMed/NCBI
|
|
86
|
Angulo I, Rodríguez R, García B, Medina M,
Navarro J and Subiza JL: Involvement of nitric oxide in bone
marrow-derived natural suppressor activity. Its dependence on
IFN-γ. J Immunol. 155:15–26. 1995.PubMed/NCBI
|
|
87
|
Brooks JC and Hoskin DW: The inhibitory
effect of cyclophosphamide-induced MAC-1+ natural suppressor cells
on IL-2 and IL-4 utilization in MLR. Transplantation. 58:1096–1103.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kusmartsev SA, Li Y and Chen SH: Gr-1+
myeloid cells derived from tumor-bearing mice inhibit primary T
cell activation induced through CD3/CD28 costimulation. J Immunol.
165:779–785. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Rodriguez PC, Zea AH, DeSalvo J, Culotta
KS, Zabaleta J, Quiceno DG, Ochoa JB and Ochoa AC: L-arginine
consumption by macrophages modulates the expression of CD3 ζ chain
in T lymphocytes. J Immunol. 171:1232–1239. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Bronte V, Serafini P, Mazzoni A, Segal DM
and Zanovello P: L-arginine metabolism in myeloid cells controls
T-lymphocyte functions. Trends Immunol. 24:302–306. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kusmartsev S, Nefedova Y, Yoder D and
Gabrilovich DI: Antigen-specific inhibition of CD8+ T cell response
by immature myeloid cells in cancer is mediated by reactive oxygen
species. J Immunol. 172:989–999. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Schmielau J and Finn OJ: Activated
granulocytes and granulocyte-derived hydrogen peroxide are the
underlying mechanism of suppression of T-cell function in advanced
cancer patients. Cancer Res. 61:4756–4760. 2001.PubMed/NCBI
|
|
93
|
Hanson EM, Clements VK, Sinha P, Ilkovitch
D and Ostrand-Rosenberg S: Myeloid-derived suppressor cells
down-regulate L-selectin expression on CD4+ and CD8+ T cells. J
Immunol. 183:937–944. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Li H, Han Y, Guo Q, Zhang M and Cao X:
Cancer-expanded myeloid-derived suppressor cells induce anergy of
NK cells through membrane-bound TGF-β 1. J Immunol. 182:240–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Rodriguez PC, Hernandez CP, Quiceno D,
Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J and Ochoa AC: Arginase
I in myeloid suppressor cells is induced by COX-2 in lung
carcinoma. J Exp Med. 202:931–939. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Taheri F, Ochoa JB, Faghiri Z, Culotta K,
Park HJ, Lan MS, Zea AH and Ochoa AC: l-Arginine regulates the
expression of the T-cell receptor ζ chain (CD3ζ) in Jurkat cells.
Clin Cancer Res. 7:958–965. 2001.
|
|
97
|
Bernard AC, Mistry SK, Morris SM Jr,
O'Brien WE, Tsuei BJ, Maley ME, Shirley LA, Kearney PA, Boulanger
BR and Ochoa JB: Alterations in arginine metabolic enzymes in
trauma. Shock. 15:215–219. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ichihara F, Kono K, Sekikawa T and
Matsumoto Y: Surgical stress induces decreased expression of
signal-transducing ζ molecules in T cells. Eur Surg Res.
31:138–146. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Park KG, Heys SD, Blessing K, Kelly P,
McNurlan MA, Eremin O and Garlick PJ: Stimulation of human breast
cancers by dietary L-arginine. Clin Sci. 82:413–417. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Pan PY, Zang Y, Weber K, Meseck ML and
Chen SH: OX40 ligation enhances primary and memory cytotoxic T
lymphocyte responses in an immunotherapy for hepatic colon
metastases. Mol Ther. 6:528–536. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Makarenkova VP, Bansal V, Matta BM, Perez
LA and Ochoa JB: CD11b+/Gr-1+ myeloid suppressor cells cause T cell
dysfunction after traumatic stress. J Immunol. 176:2085–2094. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Yang L, DeBusk LM, Fukuda K, Fingleton B,
Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP and Lin PC:
Expansion of myeloid immune suppressor Gr+CD11b+ cells in
tumor-bearing host directly promotes tumor angiogenesis. Cancer
Cell. 6:409–421. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Allegra A, Alonci A, Penna G, Innao V,
Gerace D, Rotondo F and Musolino C: The cancer stem cell
hypothesis: a guide to potential molecular targets. Cancer Invest.
32:470–495. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ye XZ, Yu SC and Bian XW: Contribution of
myeloid-derived suppressor cells to tumor-induced immune
suppression, angiogenesis, invasion and metastasis. J Genet
Genomics. 37:423–430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Mantovani G, Macciò A, Madeddu C, Mura L,
Gramignano G, Lusso MR, Massa E, Mocci M and Serpe R: Antioxidant
agents are effective in inducing lymphocyte progression through
cell cycle in advanced cancer patients: assessment of the most
important laboratory indexes of cachexia and oxidative stress. J
Mol Med. 81:664–673. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Szuster-Ciesielska A, Hryciuk-Umer E,
Stepulak A, Kupisz K and Kandefer-Szerszeń M: Reactive oxygen
species production by blood neutrophils of patients with laryngeal
carcinoma and antioxidative enzyme activity in their blood. Acta
Oncol. 43:252–258. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Bronte V, Kasic T, Gri G, Gallana K,
Borsellino G, Marigo I, Battistini L, Iafrate M, Prayer-Galetti T,
Pagano F, et al: Boosting antitumor responses of T lymphocytes
infiltrating human prostate cancers. J Exp Med. 201:1257–1268.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Nagaraj S, Gupta K, Pisarev V, Kinarsky L,
Sherman S, Kang L, Herber DL, Schneck J and Gabrilovich DI: Altered
recognition of antigen is a mechanism of CD8+ T cell tolerance in
cancer. Nat Med. 13:828–835. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
109
|
Nagaraj S, Schrum AG, Cho HI, Celis E and
Gabrilovich DI: Mechanism of T cell tolerance induced by
myeloid-derived suppressor cells. J Immunol. 184:3106–3116. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Yan Z, Garg SK and Banerjee R: Regulatory
T cells interfere with glutathione metabolism in dendritic cells
and T cells. J Biol Chem. 285:41525–41532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Yan Z, Garg SK, Kipnis J and Banerjee R:
Extracellular redox modulation by regulatory T cells. Nat Chem
Biol. 5:721–723. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Bronte V, Serafini P, Apolloni E and
Zanovello P: Tumor-induced immune dysfunctions caused by myeloid
suppressor cells. J Immunother. 24:431–446. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Salvadori S, Martinelli G and Zier K:
Resection of solid tumors reverses T cell defects and restores
protective immunity. J Immunol. 164:2214–2220. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Seung LP, Rowley DA, Dubey P and Schreiber
H: Synergy between T-cell immunity and inhibition of paracrine
stimulation causes tumor rejection. Proc Natl Acad Sci USA.
92:6254–6258. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Terabe M, Matsui S, Park JM, Mamura M,
Noben-Trauth N, Donaldson DD, Chen W, Wahl SM, Ledbetter S, Pratt
B, et al: Transforming growth factor-β production and myeloid cells
are an effector mechanism through which CD1d-restricted T cells
block cytotoxic T lymphocyte-mediated tumor immunosurveillance:
abrogation prevents tumor recurrence. J Exp Med. 198:1741–1752.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Ugel S, Delpozzo F, Desantis G, Papalini
F, Simonato F, Sonda N, Zilio S and Bronte V: Therapeutic targeting
of myeloid-derived suppressor cells. Curr Opin Pharmacol.
9:470–481. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Nefedova Y, Fishman M, Sherman S, Wang X,
Beg AA and Gabrilovich DI: Mechanism of all-trans retinoic acid
effect on tumor-associated myeloid-derived suppressor cells. Cancer
Res. 7:11021–11028. 2007. View Article : Google Scholar
|
|
118
|
Mirza N, Fishman M, Fricke I, Dunn M,
Neuger AM, Frost TJ, Lush RM, Antonia S and Gabrilovich DI:
All-trans-retinoic acid improves differentiation of myeloid cells
and immune response in cancer patients. Cancer Res. 66:9299–9307.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Talmadge JE, Hood KC, Zobel LC, Shafer LR,
Coles M and Toth B: Chemoprevention by cyclooxygenase-2 inhibition
reduces immature myeloid suppressor cell expansion. Int
Immunopharmacol. 7:140–151. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Suzuki E, Kapoor V, Jassar AS, Kaiser LR
and Albelda SM: Gemcitabine selectively eliminates splenic
Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and
enhances antitumor immune activity. Clin Cancer Res. 11:6713–6721.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Hotchkiss RS, Tinsley KW, Hui JJ, Chang
KC, Swanson PE, Drewry AM, Buchman TG and Karl IE: p53-dependent
and -independent pathways of apoptotic cell death in sepsis. J
Immunol. 164:3675–3680. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Ding ZC, Lu X, Yu M, Lemos H, Huang L,
Chandler P, Liu K, Walters M, Krasinski A, Mack M, et al:
Immunosuppressive myeloid cells induced by chemotherapy attenuate
antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. Cancer
Res. 74:3441–3453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Triozzi PL, Aldrich W and Singh A: Effects
of interleukin-1 receptor antagonist on tumor stroma in
experimental uveal melanoma. Invest Ophthalmol Vis Sci.
52:5529–5535. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Jiang J, Wang Z, Li Z, Zhang J, Wang C, Xu
X and Qin Z: Early exposure of high-dose interleukin-4 to tumor
stroma reverses myeloid cell-mediated T-cell suppression. Gene
Ther. 17:991–999. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Ko JS, Zea AH, Rini BI, Ireland JL, Elson
P, Cohen P, Golshayan A, Rayman PA, Wood L, Garcia J, et al:
Sunitinib mediates reversal of myeloid-derived suppressor cell
accumulation in renal cell carcinoma patients. Clin Cancer Res.
15:2148–2157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Ko JS, Rayman P, Ireland J, Swaidani S, Li
G, Bunting KD, Rini B, Finke JH and Cohen PA: Direct and
differential suppression of myeloid-derived suppressor cell subsets
by sunitinib is compartmentally constrained. Cancer Res.
70:3526–3536. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Pan PY, Wang GX, Yin B, Ozao J, Ku T,
Divino CM and Chen SH: Reversion of immune tolerance in advanced
malignancy: modulation of myeloid-derived suppressor cell
development by blockade of stem-cell factor function. Blood.
111:219–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Gao P, Zhang H, Dinavahi R, Li F, Xiang Y,
Raman V, Bhujwalla ZM, Felsher DW, Cheng L, Pevsner J, et al:
HIF-dependent antitumorigenic effect of antioxidants in vivo.
Cancer Cell. 12:230–238. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Hayes CS, Shicora AC, Keough MP, Snook AE,
Burns MR and Gilmour SK: Polyamine-blocking therapy reverses
immunosuppression in the tumor microenvironment. Cancer Immunol
Res. 2:274–285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Santilli G, Piotrowska I, Cantilena S,
Chayka O, D'Alicarnasso M, Morgenstern DA, Himoudi N, Pearson K,
Anderson J, Thrasher AJ, et al: Polyphenon [corrected] E enhances
the antitumor immune response in neuroblastoma by inactivating
myeloid suppressor cells. Clin Cancer Res. 19:1116–1125. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Serafini P, Meckel K, Kelso M, Noonan K,
Califano J, Koch W, Dolcetti L, Bronte V and Borrello I:
Phosphodiesterase-5 inhibition augments endogenous antitumor
immunity by reducing myeloid-derived suppressor cell function. J
Exp Med. 203:2691–2702. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Melani C, Sangaletti S, Barazzetta FM,
Werb Z and Colombo MP: Amino-biphosphonate-mediated MMP-9
inhibition breaks the tumor-bone marrow axis responsible for
myeloid-derived suppressor cell expansion and macrophage
infiltration in tumor stroma. Cancer Res. 67:11438–11446. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Valenti R, Huber V, Filipazzi P, Pilla L,
Sovena G, Villa A, Corbelli A, Fais S, Parmiani G and Rivoltini L:
Human tumor-released microvesicles promote the differentiation of
myeloid cells with transforming growth factor-β-mediated
suppressive activity on T lymphocytes. Cancer Res. 66:9290–9298.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Ghoreschi K, Laurence A and O'Shea JJ:
Selectivity and therapeutic inhibition of kinases: to be or not to
be? Nat Immunol. 10:356–360. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Egberts F, Kahler KC, Livingstone E and
Hauschild A: Metastatic melanoma: scientific rationale for
sorafenib treatment and clinical results. Onkologie. 31:398–403.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Motzer RJ, Michaelson MD, Redman BG, Hudes
GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE,
et al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Motzer RJ, Rini BI, Bukowski RM, Curti BD,
George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G,
et al: Sunitinib in patients with metastatic renal cell carcinoma.
JAMA. 295:2516–2524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Motzer RJ and Bukowski RM: Targeted
therapy for metastatic renal cell carcinoma. J Clin Oncol.
24:5601–5608. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck
M, Sung M, Schwartz M, Divino CM, Pan PY and Chen SH: The novel
role of tyrosine kinase inhibitor in the reversal of immune
suppression and modulation of tumor microenvironment for
immune-based cancer therapies. Cancer Res. 69:2514–2522. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
140
|
van Cruijsen H, Hoekman K, Stam AG, van
den Eertwegh AJ, Kuenen BC, Scheper RJ, Giaccone G and de Gruijl
TD: Defective differentiation of myeloid and plasmacytoid dendritic
cells in advanced cancer patients is not normalized by tyrosine
kinase inhibition of the vascular endothelial growth factor
receptor. Clin Dev Immunol. 2007:173152007. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Xin H, Zhang C, Herrmann A, Du Y, Figlin R
and Yu H: Sunitinib inhibition of Stat3 induces renal cell
carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Cancer Res. 69:2506–2513. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Bose A, Taylor JL, Alber S, Watkins SC,
Garcia JA, Rini BI, Ko JS, Cohen PA, Finke JH and Storkus WJ:
Sunitinib facilitates the activation and recruitment of therapeutic
anti-tumor immunity in concert with specific vaccination. Int J
Cancer. 129:2158–2170. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
North RJ: Down-regulation of the antitumor
immune response. Adv Cancer Res. 45:1–43. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Hart KM, Usherwood EJ and Berwin BL:
CX3CR1 delineates temporally and functionally distinct subsets of
myeloid-derived suppressor cells in a mouse model of ovarian
cancer. Immunol Cell Biol. 92:499–508. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Huang B, Pan PY, Li Q, Sato AI, Levy DE,
Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid
suppressor cells mediate the development of tumor-induced T
regulatory cells and T-cell anergy in tumor-bearing host. Cancer
Res. 66:1123–1131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Tomihara K, Guo M and Shin T, Sun X,
Ludwig SM, Brumlik MJ, Zhang B, Curiel TJ and Shin T:
Antigen-specific immunity and cross-priming by epithelial ovarian
carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol. 184:6151–6160.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Ko HJ, Lee JM, Kim YJ, Kim YS, Lee KA and
Kang CY: Immunosuppressive myeloid-derived suppressor cells can be
converted into immunogenic APCs with the help of activated NKT
cells: an alternative cell-based antitumor vaccine. J Immunol.
182:1818–1828. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Nausch N, Galani IE, Schlecker E and
Cerwenka A: Mononuclear myeloid-derived ‘suppressor’ cells express
RAE-1 and activate natural killer cells. Blood. 112:4080–4089.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Greifenberg V, Ribechini E, Rössner S and
Lutz MB: Myeloid-derived suppressor cell activation by combined LPS
and IFN-γ treatment impairs DC development. Eur J Immunol.
39:2865–2876. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Dolcetti L, Peranzoni E, Ugel S, Marigo I,
Gomez A Fernandez, Mesa C, Geilich M, Winkels G, Traggiai E, Casati
A, et al: Hierarchy of immunosuppressive strength among
myeloid-derived suppressor cell subsets is determined by GM-CSF.
Eur J Immunol. 40:22–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Bronte V: Myeloid-derived suppressor cells
in inflammation: uncovering cell subsets with enhanced
immunosuppressive functions. Eur J Immunol. 39:2670–2672. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Lioubin MN, Algate PA, Tsai S, Carlberg K,
Aebersold A and Rohrschneider LR: p150Ship, a signal transduction
molecule with inositol polyphosphate-5-phosphatase activity. Genes
Dev. 10:1084–1095. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Helgason CD, Damen JE, Rosten P, Grewal R,
Sorensen P, Chappel SM, Borowski A, Jirik F, Krystal G and
Humphries RK: Targeted disruption of SHIP leads to hemopoietic
perturbations, lung pathology, and a shortened life span. Genes
Dev. 12:1610–1620. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Rauh MJ, Ho V, Pereira C, Sham A, Sly LM,
Lam V, Huxham L, Minchinton AI, Mui A and Krystal G: SHIP represses
the generation of alternatively activated macrophages. Immunity.
23:361–374. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Paraiso KHT, Ghansah T, Costello A,
Engelman RW and Kerr WG: Induced SHIP deficiency expands myeloid
regulatory cells and abrogates graft-versus-host disease. J
Immunol. 178:2893–2900. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Guedez L, Jensen-Taubman S, Bourboulia D,
Kwityn CJ, Wei B, Caterina J and Stetler-Stevenson WG: TIMP-2
targets tumor-associated myeloid suppressor cells with effects in
cancer immune dysfunction and angiogenesis. J Immunother.
35:502–512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Kaimala S, Mohamed YA, Nader N, Issac J,
Elkord E, Chouaib S, Fernandez-Cabezudo MJ and Al-Ramadi BK:
Salmonella-mediated tumor regression involves targeting of tumor
myeloid suppressor cells causing a shift to M1-like phenotype and
reduction in suppressive capacity. Cancer Immunol Immunother.
63:587–599. 2014. View Article : Google Scholar : PubMed/NCBI
|
